HENGRUI PHARMA (600276.SH): Marketing Authorization Application for Aumolertinib Sulfate Tablets Accepted

Stock News11-24

HENGRUI PHARMA (600276.SH) announced that it recently received the "Acceptance Notice" from the National Medical Products Administration (NMPA), indicating that the marketing authorization application for Aumolertinib Sulfate Tablets has been accepted.

The drug has already been approved in China for four indications: 1. Treatment of adult patients with active ankylosing spondylitis who have shown inadequate response or intolerance to one or more TNF inhibitors. 2. Treatment of adult patients with moderate-to-severe active rheumatoid arthritis who have shown inadequate response or intolerance to one or more TNF inhibitors. 3. Treatment of adult patients with moderate-to-severe atopic dermatitis who have shown inadequate response or intolerance to topical or other systemic therapies. 4. Treatment of adult patients with severe alopecia areata.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment